Site
Jehangir Clinical Development Centre Pvt Ltd (Pune, India)
IND activated KRI 0.0Principal investigator Dr. Tanaka
Patients
1
Active
0
enrolled or consented
Withdrawn
0
Serious AEs
1
Open QA findings
0
Aged data queries
0
Studies & contracts
total budget 54500.00 USD
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Phase II
study completed
contract executed
54500 USD
Patients first 1
| Ref | Status | Consented | Study |
|---|---|---|---|
| P2B-064 | completed | 2012-12-23 | A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma |
Luna participants 0
Safety
6 AEs · 1 serious
serious
P2B-064
assessed
Grade 3 pyrexia with onset in cycle 4 (2013-03-25); serious (hospitalization); assessed as not related to study drug (not related); resolved 2013-03-28.
QA findings
0 open
No findings recorded
Findings are filed by monitoring visits.
Monitoring visits 0
No visits recorded
Re-score risk to propose an on-site visit.
Payments 0
No payments on file
Milestone payments are proposed by the finance step and approved in the review queue.